Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction77
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging74
Best of 2022 in prostate cancer and prostatic diseases66
Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer66
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?61
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?58
Germline alterations among Hispanic men with prostate cancer53
Sexual outcomes in men who have sex with men who underwent radical prostatectomy49
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study46
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)46
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer44
New BPH therapy classification: what really FITs?42
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions40
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches33
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study31
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis30
More evidence that physical activity is beneficial for prostate cancer30
Concerns regarding prostate cancer screening guidelines in minority populations29
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States29
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro29
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer29
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations29
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer28
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study28
TRexit is going one step further28
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer27
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis26
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts26
0.20049405097961